CYPA · Cyphaira Corp.
$1.22
At close · Jun 30
Going-concern doubt
— flagged Nov 14, 2022
Substantial doubt about the company's ability to continue as a going concern.
“This raises substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2022
Market Cap
$20.70M
Shares
16.97M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.22
Open$1.22
Day$1.22–1.22
Available close range$1.05–3.00
Avg vol available · 20d380
Short vol100%
DataMar 2024–Jun 2026
Filing10-Q · Nov 14
The closing range uses available history since Jul 24, 2025; less than a full year is stored.
Up next
filed Nov 14, 2022
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+48.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$67,941
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
RSI (14)
58
neutral
52-week position
9%
near low
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
1189%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
23.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
RSI (14)
58
Neutral
52-week position
9%
Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $1
Now $1 · 9%
Range high $3
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYPA
this stock
Cyphaira Corp.
|
$20.70M | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$59.80B | +22.2% | — | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.49B | +25.6% | +4.3% | 64.0 | 3.2% |
|
GALDY
Galderma Group AG/ADR
|
$44.48B | -8.0% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYPA | -19.7% | — | — | -18.1% | -59.3% |
| SPY | +1.8% | -1.6% | +7.9% | -1.3% | +9.5% |
| vs SPY | -21.5% | — | — | -16.8% | -68.8% |